

ASX/Media Release

18/09/2020

Results of General Meeting

Emerald Clinics Limited (ASX: EMD) (Emerald or the Company), a Real-World Evidence company that develops remote patient monitoring technologies underpinned by a clinical services model, advises that a General Meeting of shareholders was held today, 18 September 2020. The resolution put to the meeting were passed on a poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll result and the proxies received in respect of the resolution are set out below:

Poll Results

Resolutions	For	Against	Abstain
1 – Approval of change of Company name	105,910,156	-	-

Summary of Proxy Votes Received

Resolutions	For	At Proxy Holders Discretion	Against	Abstain
1 – Approval of change of Company name	63,751,779	287,778	-	-

Release authorised by: Dr Michael Winlo, CEO and Managing Director

For further information:

Dr Michael Winlo
CEO
(08) 6559 2800
investors@emeraldclinics.com.au

Matt Wright
Media/investor relations
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Emerald Clinics Limited

Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company focussed on generating Real-World Evidence using its network of specialist medical clinics and purpose-built, remote patient monitoring software and technology. The Emerald model provides care while also co-creating high quality and ethically sourced clinical data from informed and consenting patients. Emerald's evidence is used to accelerate the development of new treatments and models of care. Emerald customers pay for deidentified data, clinical trials and consulting services or monitor their workforce.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would,"

“could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.